
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Candel Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Candel & IDEA Pharma Partner to Advance CAN-2409 Commercialization Efforts
Details : Under this partnership, IDEA will provide strategic commercial input throughout the development and commercialization process for Candel’s lead asset, CAN-2409 (aglatimagene besadenovec).
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
March 20, 2025
Lead Product(s) : Aglatimagene Besadenovec,Valacyclovir
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Candel Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
